Kiora Pharmaceuticals has been granted US and European patents covering local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules.
By Mike Pears and Joel Beevers, Patent Attorneys at Potter Clarkson
January 1, 2021 marked the UK’s official separation from the EU and with that has come a raft of changes to how the nation will now do business with the rest of the world.
Two US government agencies are investigating whether Moderna Therapeutics, the biotech company behind one of the leading Covid-19 vaccine candidates, was upfront about government funding in its filed or awarded patents, as required by federal law.
The US District Court for the District of New Jersey ruled in Amgen’s favor on the validity of the two patents on Enbrel and the methods for making it.
GE Healthcare says a new inflatable bioreactor bag configured in perfusion mode can achieve a cell density over four times that of the current industry standard.
A UK judge says a vexatious litigation strategy is staving off Humira biosimilars, but AbbVie is “playing by the rules and incurring the costs of doing so,” according to an IP lawyer.
US intellectual property (IP) rules and a string of recent court cases are reducing the types of inventions pharma companies can patent, and “calling into question entire portfolios,” says a specialist lawyer.
Juno Therapeutics has agreed to settle litigation with Novartis and the Trustees of the University of Pennsylvania after Juno entered into a December 2013 license agreement with St. Jude Children’s Research Hospital, which owned the patent rights.
Marinomed Biotechnologies is set to take on the ‘common cold’ in China with a new patent for an anti-viral polymer technology that prevents rhinovirus infection.
Sartorius Stedium Biotech (SSB) and GE Healthcare Life Sciences say new cross licensing deal will aid development of their respective biomanufacturing tech offerings.
Improving safety and efficacy coupled with drug industry desire for “stronger” patents will drive growth of the biologics sector over the next five years, according to new research.
